Loading...
HomeMy WebLinkAbout101922 New cancer diagnostic tests will soon get the same old rigor________________________________ ALERT: BE CAUTIOUS This email originated outside the organization. Do not open attachments or click on links if you are not expecting them. ________________________________ Assessing new cancer diagnostics | Landmark philanthropic gift to Fred Hutch | Refining gene therapy for herpes ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ View as Web page <https://secure.fredhutch.org/site/R?i=MeeNpE_bt0wIdxAaPJkZ2uA7rlzZgbf2l3YbqQmj45NHVsmLoCxCqw> <https://secure.fredhutch.org/site/R?i=CU1kJNvkWpntiKPAJx1dsHuH3wCEO0C0NPdACR7yzUsiNCFguDkqrg> <https://secure.fredhutch.org/images/content/pagebuilder/fhcc-eml-hdr-shadow.png> <https://secure.fredhutch.org/site/R?i=GIaLPWHkQl7z06CH68fzyJNiveMmLFLVdobpWgk6ghcvU4kRhVEAwA> October 19, 2022 ⋅ A monthly digest of the latest from Fred Hutch New $7.4M grant will support assessment of cancer diagnostics <https://secure.fredhutch.org/site/R?i=0RFDUOV7GCikh_rTuG0_-LczJR5s4Lg12s5fh_1KLHoZ4qYbTokDeA> Dr. Ruth Etzioni has received a seven-year Outstanding Investigator Award (OIA) from the National Cancer Institute so the Fred Hutchinson Cancer Center biostatistician can pursue “Modeling and Analytics for Novel Cancer Diagnostics.” The award, which comes with around $7.4 million in funding, will allow Etzioni, holder of the Rosalie and Harold Rea Brown Endowed Chair, and her team to build frameworks and tools to evaluate novel cancer diagnostics such as new nuclear imaging modalities and multi-cancer early detection tests, commonly referred to as liquid biopsies. “The rapid pace at which new technologies are entering the marketplace makes rigorous evaluation via controlled studies infeasible for all but a few,” she said. “This means that while we typically have some data about diagnostic test performance, we frequently lack evidence regarding the outcomes that drive clinical and policy decisions.” Etzioni plans to tackle this “data-evidence divide” by using modeling and analytics, tools she has honed over several decades investigating the benefits and harms of various types of cancer screening <https://secure.fredhutch.org/site/R?i=xqGAbAludG_0oWY-Xu6QKFPyjY-9zk-evihl7NWBoADmWJN9bEYpUw> . At the same time at Fred Hutch, Dr. Gavin Ha will be working to enhance <https://secure.fredhutch.org/site/R?i=XADnFhiFsjmaxyGoxEhTKZk9AqCRk8U0XnGGuRx0RUd1qRxp04T0IA> the information that scientists and cancer doctors can glean from liquid biopsies — blood samples with traces of DNA that provide molecular information about tumors — to improve cancer diagnosis, treatment selection and disease monitoring. The computational biologist received a 2022 National Institutes of Health Director’s New Innovator Award to fund this work. ________________________________ Landmark $710.5 million gift to accelerate cancer and infectious disease research <https://secure.fredhutch.org/site/R?i=UACPdBookZoCMddQh4qzOqJ2G1rZUmtBBg9FE1yekS6aPzMwiq4eNQ> <https://secure.fredhutch.org/site/R?i=ISQYiDrU3ULp7AbQchKXVlEigrvuUT-1_mVY9OLTSzxFKWnXggpkfw> The Bezos family is committing $710.5 million <https://secure.fredhutch.org/site/R?i=Co9-TlEbyeDqoXaTjZ72g8CD5YSwt3Aoztz2pgF-pm02Y9MRuTxAbw> over the next 10 years to radically scale and speed what Fred Hutchinson Cancer Center does best: Using fundamental science to answer the most complex biological questions and translating the answers into new ways to prevent, treat and cure cancer and infectious diseases. ________________________________ The Latest New approach could make bone marrow transplantation safer, stronger <https://secure.fredhutch.org/site/R?i=G9emZCQ_A4FkQQ1gCxGWXC9N8u4g64hmuXv09KFgxeefeUA7ovL3cg> A Fred Hutch team has developed an approach for bone marrow transplants that clears away the immune cells underpinning GVHD, then boosts the anti-tumor activity of the immune cells left behind. The team, led by Dr. Geoff Hill, found the approach prevented relapse in laboratory models of leukemia and multiple myeloma treatments. Fred Hutch hosts inaugural Dr. E. Donnall Thomas Symposium <https://secure.fredhutch.org/site/R?i=WKdNJeUTTPPCyH48adQJh4mG4JD7avtENgjC-MHD0VY-uvoblzlP9A> Researchers from around the globe visited Seattle to honor the Nobel Prize-winning scientist and to discuss the future of bone marrow transplantation, gene and cellular therapies at the inaugural Dr. E. Donnall Thomas Symposium. Researchers refine experimental gene therapy for herpes <https://secure.fredhutch.org/site/R?i=TvEfpVDudfNxr2jdrKF6Jai7aK1STCy6OwOFRmq18E8iLcbWQQm-4A> Two years after scientists showed that an experimental gene therapy for herpes can knock out most latent infection in mice, new tests reveal that it also suppresses the amount of transmissible virus shed by the treated animals. Specialty clinic leads with multidisciplinary team approach <https://secure.fredhutch.org/site/R?i=6FZjcoDZJtAwYMweUN6435g5k91t2jD_qM2oOTEg2DGA3hHTr7G96g> The Breast Cancer Specialty Clinic’s multidisciplinary team approach was the right fit for Teresa Campagna, a 33-year-old diagnosed with early-stage invasive ductal carcinoma that testing revealed carried two mutations, in the genes BRCA1 and CHEK2, that put her at higher risk of developing breast cancer. Colorectal cancer patient is committed to advocacy <https://secure.fredhutch.org/site/R?i=K5LARMJKpP_jBk26EWMy6qCnjvsibJQ15B9N6ufoJwAil7oAdI76Eg> Natalie Phelps first started suspecting that something wasn’t quite right in January 2020. Nearly eight months pregnant at the time, her midwife attributed the pain she was experiencing to pregnancy or maybe hemorrhoids. ________________________________ Good News Fred Hutch begins rollout of new brand <https://secure.fredhutch.org/site/R?i=Ufj0HYcHwdzMPIkAvnQsQ0QUwbAdH0v97n04L7zgWI8n9ndkfBAyjA> Fred Hutchinson Cancer Center began the rollout of a new brand and logo that represent the combined science and lifesaving skills of its single unified organization. “Unifying Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center will enable us to accelerate our shared mission of putting the world’s most devastating diseases behind us,” said President and Director Dr. Thomas J. Lynch Jr. Understanding tribal communities and cancer through storytelling, art <https://secure.fredhutch.org/site/R?i=X1-Rs4aI6EbsgogPvaKdDQMmh4r66SwQDMaxa3MgoVf-EymCqWFS7Q> Fred Hutch’s Public Art and Community Dialogue Program selected artist, storyteller and Lower Elwha S’Klallam Tribe member Roger Fernandes to create new mural. Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow <https://secure.fredhutch.org/site/R?i=LA8nV4LzrErYWVJXV-h_YPFndPSernyXmcFVwYSlpydJthMCstNoAA> Salisbury became the third recipient of the Brave Fellowship at Fred Hutch. Funded by Brooks Running on behalf of the Brave Like Gabe Foundation, the goal of the fellowship is to develop scientific leaders who will advocate for a diverse and inclusive biomedical research workforce focused on rare cancer research. Dr. Anat Zimmer receives AAUW fellowship <https://secure.fredhutch.org/site/R?i=NrdxjHdOow8KAzDUEs9nHBODCr-lG263lOWw-2IxuYtpUyx1z2oVcQ> The computational biologist in Dr. Gavin Ha’s lab was awarded a 2022-23 fellowship by the American Association of University Women, which offers monetary awards to alleviate financial stress so women can focus on their educational and career aspirations. ________________________________ Help the next cure happen faster Your partnership makes lifesaving discoveries possible. <https://secure.fredhutch.org/site/R?i=94iemhwVSvWgEK8vR-NzkmCz8nE6LxXMONdiMnztOIUzbHNkhXGdDg> ________________________________ Share this newsletter with family or friends <https://secure.fredhutch.org/site/R?i=-eGNMdUWy5l38igtFx22R4ZkcQRRxhWl3acWWuuiFp2HqK02_GC0EQ> <https://secure.fredhutch.org/site/R?i=bk4zFtBnQe_OY2TM-pmXEMARNia5GhWgFFBoLXyLaJvavtq5XpAPaw> 1100 Fairview Ave. N., Seattle, WA 98109 communications@fredhutch.org <https://secure.fredhutch.org/site/R?i=qSTKnp1LvsyqSv0q8Hb3I2DCPLXMVNE0d8RClIIVfw7vxRRMFbLyPA> 206.667.5000 <https://secure.fredhutch.org/site/R?i=9u-vmxKREX229Hwu9dFG_8IrSqMYSC9KAhiYJrykUxJ1CfhtgWXubw> <https://secure.fredhutch.org/site/R?i=ZKNRWWJsE1RRHFZuiUmx8CNasgfr12pBjxjDXpHDzc55Poh4963L5w> <https://secure.fredhutch.org/site/R?i=RWcIPjqAz0qGiYRk2Ap1Lf1PM95USM5Oqafqzbg9AdzjtlcjNGjjlQ> <https://secure.fredhutch.org/site/R?i=baIicvShbmO3W-bG-xC0-CIpX5bDu_zsCCOQy_4qUMbar6vBkAj8Xg> ________________________________ Fred Hutchinson Cancer Center is a 501(c)(3) nonprofit organization. You can adjust your email preferences <http://engage.fredhutch.org/site/CO?i=vuVOO3Kl9ETJhe1n1qIFg5GVz06ayE8GwmPvBR9oXwictn-jC9WbXu7jT-m7f4Dz&cid=1021> at any time or contact us at optout@fredhutch.org <https://secure.fredhutch.org/site/R?i=bsQ5VsFcHYTWCl0DlUrRL8Mpd9dLqwtVtWlqMoXFvy1FJkLupOsT3A> to be removed from both mail and email lists. For information about our privacy practices, see our Privacy Policy <https://secure.fredhutch.org/site/R?i=qZQo6wXE0wBBDlpkYDeL9qQzLs8977I32k1AOSViUq2utaVd4ySiuw> . © 2022 Fred Hutchinson Cancer Center. All rights reserved. <http://engage.fredhutch.org/site/PixelServer?j=4RxyomP_-pitGimZWmU8WLfDGDBICVob-e57xI6IpoCGSzpzG0_zPQ> /alternative; boundary="NextPart_25776441_3abe_4a15_b401_f2ddaacb85f4" X-BESS-ID: 1666234138-103945-5352-43862-1 X-BESS-VER: 2019.1_20221004.2324 X-BESS-Apparent-Source-IP: 216.235.195.169 X-BESS-Spam-Status: SCORE=0.00 using global scores of QUARANTINE_LEVEL=N/A KILL_LEVEL=5.0 tests=ADVANCE_FEE_1, HTML_MESSAGE Received-SPF: pass (mx-inbound15-105.us-east-2a.ess.aws.cudaops.com: domain of email_feedback_handler@bbcsreturn.convio.net designates 216.235.195.169 as permitted sender) X-BESS-Spam-Report: Code version 3.2, rules version 3.2.2.243578 [from cloudscan15- 210.us-east-2a.ess.aws.cudaops.com] Rule breakdown below pts rule name description ---- ---------------------- -------------------------------- 0.00 ADVANCE_FEE_1 META: Appears to be advance fee fraud (Nigerian 419) 0.00 HTML_MESSAGE BODY: HTML included in message X-BESS-Spam-Score: 0.00 X-BESS-BRTS-Status: 1 X-Barracuda-Connect: outbound-ip106a.ess.barracuda.com[209.222.82.248] X-Barracuda-Start-Time: 1666234141 X-Barracuda-URL: https://10.10.14.240:443/cgi-mod/mark.cgi X-Barracuda-License: Expired X-Barracuda-BRTS-Status: 1 X-Virus-Scanned: by bsmtpd at co.jefferson.wa.us X-Barracuda-Scan-Msg-Size: 37425 Return-Path: email_feedback_handler@bbcsreturn.convio.net X-MS-Exchange-Organization-Network-Message-Id: 261bf42d-29b9-410e-1f8b-08dab245f34e X-MS-Exchange-Organization-AuthSource: mail2013ca1.internal.county.domain X-MS-Exchange-Organization-AuthAs: Anonymous